Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) Equity Average (2016 - 2025)

Voyager Therapeutics' Equity Average history spans 11 years, with the latest figure at $208.0 million for Q4 2025.

  • For Q4 2025, Equity Average fell 33.99% year-over-year to $208.0 million; the TTM value through Dec 2025 reached $208.0 million, down 33.99%, while the annual FY2025 figure was $247.9 million, 7.51% down from the prior year.
  • Equity Average for Q4 2025 was $208.0 million at Voyager Therapeutics, down from $231.9 million in the prior quarter.
  • Across five years, Equity Average topped out at $338.2 million in Q2 2024 and bottomed at $68.0 million in Q2 2022.
  • The 5-year median for Equity Average is $196.9 million (2023), against an average of $187.5 million.
  • The largest annual shift saw Equity Average crashed 44.89% in 2022 before it surged 205.91% in 2023.
  • A 5-year view of Equity Average shows it stood at $91.2 million in 2021, then fell by 23.91% to $69.4 million in 2022, then soared by 197.13% to $206.3 million in 2023, then skyrocketed by 52.73% to $315.0 million in 2024, then plummeted by 33.99% to $208.0 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Equity Average are $208.0 million (Q4 2025), $231.9 million (Q3 2025), and $258.3 million (Q2 2025).